Iovance Biotherapeutics (IOVA)
(Real Time Quote from BATS)
$9.70 USD
-0.22 (-2.22%)
Updated Aug 12, 2024 03:08 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
Iovance Biotherapeutics, Inc. [IOVA]
Reports for Purchase
Showing records 161 - 180 ( 190 total )
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Further Preparations for Commercial Success; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Shocker (Not), LN-145 Granted Breakthrough Therapy Designation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASCO Melanoma Abstract Data Continue to Solidify Confidence in Pivotal Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q19 Results; Upcoming Inflection Points at ASCO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Important Chess Moves to Head Regulatory Agencies off at the Pass
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Iovance Officially Goes Pivotal; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TIL Persistence in Patients and Continued Case for Polyclonal Approach; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2018 results; Building the Foundation for TILs in Solid Tumors; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
What We''ve All Been Waiting For, Plus RMAT and a Chunk of Cash; Price Target Raised to $26
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Updated Moffitt Lung Data in Intractable Population Point in Right Direction
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Our Thoughts Post Investor Dinner Event With NSCLC KOL
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q18 Results; Watchful Waiting Ahead of FDA Meeting This Quarter; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Recent News in Space Supportive of Thesis, Not Recent Weakness; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Increased Momentum; Expanding Melanoma Study; Developing Next Gen Manufacturing
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2017 Results; Exciting Times Ahead for TILs
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
On the Road to Takeout; Profiling Continued Differentiation vs. CAR-T; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Nice Early Peek as the Plan Is Starting to Come Together; Target Boosted to $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Regulatory Visibility and Hopefully Game Changing Data for Solid Tumors in 2018
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J